Brevan Howard Capital Management’s Corcept Therapeutics CORT Stock Holding History

Brevan Howard Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,016	Closed	-$323K	–	2154
2026 Q1	$323K	Buy	8,016 +718	+10%	+$26.8K	﹤0.01%	1575
2025 Q4	$254K	Buy	7,298 +3,957	+118%	+$311K	﹤0.01%	1457
2025 Q3	$278K	Sell	3,341 -41,661	-93%	-$3.01M	﹤0.01%	1601
2025 Q2	$3.3M	Buy	+45,002	New	+$3.26M	0.02%	533
2025 Q1	–	Sell	-8,423	Closed	-$424K	–	1204
2024 Q4	$424K	Buy	+8,423	New	+$441K	﹤0.01%	667

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's CORT Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 8,016 shares — an estimated $323K sold.

Brevan Howard Capital Management first reported a position in CORT in Q4 2024 and held it in 5 quarters. The position peaked at $3.3M in Q2 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Brevan Howard Capital Management reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 8,016 Corcept Therapeutics shares in Q2 2026, an estimated $323K.
Brevan Howard Capital Management first reported a position in Corcept Therapeutics in Q4 2024 and held it in 5 quarters.
Brevan Howard Capital Management's Corcept Therapeutics position peaked at $3.3M in Q2 2025.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.